Table 2.
Follow-up CMR measurements of wall thickening and subacute blood flow by 82Rb-PET on segmental level
| Hypokinetic | Normal | Hyperkinetic | P value | |
|---|---|---|---|---|
| Segments (n) | 238 | 263 | 59 | |
| Wall thickening (%) | 31 (11–45)*,¶ | 70 (57–86) | 118 (108–128) | <.001 |
| Wall motion (mm) | 4.7 (2.4–7.1) *,¶ | 8.1 (5.9–10.6) | 10.3 (7.9–12.3) | <.001 |
| LGE follow-up, % of segment | 13.8 (0–45.7)*,¶ | 0 (0–10.0) | 0 (0–1.9) | <.001 |
| 82Rb—extent of severe hypoperfusion (% of segment) | 13 (0–72)*,¶ | 0 (0-23) | 0 (0–11) | <.001 |
| 82Rb—absolute blood flow (ml·min·g) | 0.81 (0.63–1.02)*,¶ | 0.97 (0.78–1.20) | 1.22 (0.93–1.34)* | <.001 |
Measurements from follow-up wall thickening and wall motion with CMR and subacute setting PET-Rb. Values are median (IQR). AHA-16 model segments of abnormal, normal, hyperkinetic wall thickening as measured by CMR and stratified according to normal database
LGE follow-up, late gadolinium enhancement at follow-up per segment; Rb, Rubidium-82 median (IQR) percent of extent severe hypoperfusion per segment, absolute blood flow in ml·min·g
*P < .001 for difference vs. normal wall thickening segments
¶P < .02 for difference vs. hyperkinetic wall thickening segments